European and U.S. Funding initiatives are converging to accelerate cancer research and innovation, with a surge in grant opportunities ranging from early-stage venture competitions to multi-million euro collaborative projects. The European Commission’s Horizon Europe program is spearheading significant investment, alongside seed funding from U.S. Institutions and oncology-focused startup challenges.
Two Horizon Europe Mission Cancer calls are particularly noteworthy. The first, CANCER-01, will allocate €35 million to projects developing Virtual Human Twin (VHT) models to improve understanding of cancer onset and progression, and to personalize treatment approaches. The initiative aims to make VHT-based solutions accessible through platforms like UNCAN.eu, emphasizing open science principles for data and model sharing. Expected EU contributions per project range from €8 million to €9 million, with funding for approximately four projects. The deadline for submissions is currently unspecified.
The second Horizon Europe call, CANCER-03, will distribute €22.19 million to support pragmatic clinical trials focused on immunotherapy for refractory cancers. The trials are expected to prioritize real-world effectiveness and generate evidence directly applicable to clinical practice. Randomized or cluster-randomized, investigator-initiated trials are sought, with a focus on overall survival and patient-reported outcomes, developed in collaboration with patients and their families. Approximately three projects will be funded, with each receiving an EU contribution of €7 million to €8 million. The submission deadline for CANCER-03 is September 15, 2026.
Across the Atlantic, several U.S.-based opportunities are available. The Cancer Center at Illinois is offering seed grants of up to $200,000 over two years to interdisciplinary teams for cancer-focused collaborations, with a focus on generating preliminary data for larger grant applications. Proposals are due March 11, 2026, and award notifications are expected by May 13, 2026.
Johns Hopkins’ Colorectal Cancer Center of Research Excellence (CRC CORE) is providing pilot funding for novel colorectal cancer research programs, offering two awards of $60,000 each for one year. Applications are due March 2, 2026, with funding decisions announced by April 3, 2026, and projects commencing May 1, 2026.
The University of Colorado Cancer Center is offering collaborative pilot grants of up to $100,000 for 24 months to support innovative ovarian cancer research. Proposals are due March 31, 2026, with study section review scheduled for May 14, 2026, and anticipated award start dates in July 2026.
AIM-HI, a venture firm, is hosting two oncology-focused startup competitions with deadlines in mid-March 2026. The BRACE Award competition seeks startups addressing cancers prevalent in underserved populations, offering seed funding, coaching, and network access. The Women’s Venture Competition aims to empower women scientist-entrepreneurs in oncology, with similar benefits. Both competitions offer honorariums and potential further investment consideration.
The UAMS COBRE Center for Studies of Host Response to Cancer Therapy is funding pilot projects focused on understanding and mitigating the side effects of cancer treatment, offering up to $100,000 in direct costs for one year. Applications are due March 15, 2026.
the SickKids Meagan Bebenek Neuro-Oncology Fellowship offers 1-3 years of training in paediatric neuro-oncology, with applications due April 30, 2026, for the 2027-2028 academic year. The Markey Cancer Survivorship Research Initiative Pilot Award provides $10,000 to Markey members for cancer survivorship research, with a rolling application process until funds are allocated.
The convergence of these funding opportunities in mid-March necessitates prompt action from researchers and entrepreneurs pursuing pilot data, oncology entrepreneurship, or large-scale EU translational infrastructure projects.
